Achillion Pharmaceuticals Inc. recently moved its headquarters from New Haven, Connecticut to Blue Bell, PA — a suburb of Philadelphia in Montgomery County.
The pharmaceutical company focuses on developing therapies for “orphan diseases” that affect thousands of Americans.
Our region’s lower cost of doing business compared to other major cities and flourishing talent pool were the ultimate deciding factors to move 200 miles south to Greater Philadelphia.
The CEO of Achillion, Joe Truitt, stated, “We came here because of the favorability of this region, based on the most important thing — talent. Biotech development and commercialization talent.”
While considering other locations, Truitt, a Philadelphia-native, shared that the suburbs of Philadelphia are filled with “Merck, Pfizer, GSK, and Johnson & Johnson” veterans, all of whom are ideal candidates for Achillion’s 30 new, high-paying management positions.
Many companies have been interested in our region due to our diverse and skilled talent. Another medical technology company, Proscia, relocated their headquarters to Philadelphia due to our region’s talent.